Shares of Grail (NASDAQ: GRAL), a multi-cancer early detection company, surged over 13% following an optimistic presentation at the JPMorgan Healthcare Conference. The company projects 2025 revenue of $147 million to $148 million, primarily from its Galleri test, and anticipates a 22% to 32% revenue growth for Galleri in 2026. Grail has successfully reduced its cash burn to $274 million in 2025 and maintains a cash position of $904 million, ensuring operational sustainability through 2030.
Loading PerspectiveSplit analysis...
